|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2B
|
|
pubmed:dateCreated |
2001-6-8
|
|
pubmed:abstractText |
Tamoxifen had been used to treat advanced prostate cancer with limited success. In vitro data suggested that tamoxifen could enhance the cytotoxic effect of chemotherapeutic agents, including doxorubicin, on prostate cancer cell lines. We applied this observation into a phase II trial for patients with hormone refractory prostate cancer (HRPC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0250-7005
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1385-90
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:11396219-Aged,
pubmed-meshheading:11396219-Aged, 80 and over,
pubmed-meshheading:11396219-Antineoplastic Agents, Hormonal,
pubmed-meshheading:11396219-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11396219-Doxorubicin,
pubmed-meshheading:11396219-Fluorouracil,
pubmed-meshheading:11396219-Follow-Up Studies,
pubmed-meshheading:11396219-Humans,
pubmed-meshheading:11396219-Leucovorin,
pubmed-meshheading:11396219-Male,
pubmed-meshheading:11396219-Middle Aged,
pubmed-meshheading:11396219-Pilot Projects,
pubmed-meshheading:11396219-Prostate-Specific Antigen,
pubmed-meshheading:11396219-Prostatic Neoplasms,
pubmed-meshheading:11396219-Survival Rate,
pubmed-meshheading:11396219-Tamoxifen,
pubmed-meshheading:11396219-Treatment Failure,
pubmed-meshheading:11396219-Treatment Outcome
|
|
pubmed:articleTitle |
A pilot study of AFL-T (doxorubicin, 5-fluorouracil, leucovorin, and tamoxifen) combination chemotherapy for hormone-refractory prostate cancer.
|
|
pubmed:affiliation |
Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
